Given the central role of the androgen receptor (AR) in prostate cancer cell biology, AR-targeted therapies have been the backbone of prostate cancer treatment for over 50 years. New data indicate that AR is expressed in additional cell types within the tumor microenvironment. Moreover, targeting AR …
Ivy Riano: Tips to advise on how to plan your ASCO annual meeting / ASCO, ASCO Annual Meeting, cancer, Dartmouth-Hitchcock, early career oncologists, Ivy
Ivy Riano: Tips to advise on how to plan your ASCO annual meeting / ASCO, ASCO Annual Meeting, cancer, Dartmouth-Hitchcock, early career oncologists, Ivy
Don’t miss out on an engaging Tweetorial by Florez Lab and Young Lung Cancer Initiative / cancer, Florez Lab, Lung cancer, OncoDaily, Oncology, tweetorial,
Toni Choueiri: The February ASCO Plenary Series are here / ASCO, ASCO Plenary Series, cancer, DREAMM-7, FRUTIGA, gastric/GE junction adenocarcinoma,
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive…
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive…
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive…
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive…
